The Korean Journal of Blood Transfusion : eISSN 2383-6881 / pISSN 1226-9336

Table. 1.

Table. 1.

Patient characteristics, medical history, and characteristics of autoantibodies

No Age Sex Immune checkpoint inhibitor Diagnosis Treatmentcycles Interval*(weeks) Transfusionhistory Concomitantmedication Hemolysis ABO/RhD typing discrepancy Antibody screening Antibodyidentification DAT
Name Class Poly-specific Anti-IgG Anti-C3d
1 59 F Pembrolizumab Anti-PD1 GB cancer, SqCCa 6 7 Yes Cisplatin, gemcitabine No Extra-serum Negative Cold autoantibody Undone
2 47 M Durvalumab Anti-PD-L1 AGC, tubular ADC 3 12 Yes Cerelasertib No No Positive Warm autoantibody Undone
3 51 F Pembrolizumab MK-1308 Anti-PD1
Anti-CTLA-4
NSCLC, pleomorphic carcinoma 26 110 No None No No Positive Cold autoantibody Undone
4 76 M Atezolizumab Anti-PD-L1 NSCLC, SqCCa 2 26 No None Yes No Positive Warm autoantibody
Cold autoantibody
Anti-E, c, P1 alloantibody
2+ 2+
5 81 F Pembrolizumab Anti-PD1 NSCLC, SqCCa 2 3 Yes None No Extra-serum Negative Cold autoantibody +/– +/–
6 51 M Durvalumab
Tremelimumab
Anti-PD-L1
Anti-CTLA-4
HCC 29
4
129 Yes None No No Positive Cold autoantibody 1+ 1+
7 68 M Pembrolizumab Anti-PD1 CCC 2 12 Yes None No Extra-serum Negative Cold autoantibody 1+ 1+
8 67 M Nivolumab Anti-PD1 AGC, signet ring cell carcinoma 3 6 No None No Extra-serum Negative Cold autoantibody
Anti-P1
9 67 M Nivolumab Anti-PD1 AGC, tubular ADC 1 4 Yes None No Extra-serum Negative Cold autoantibody
10 65 M Pembrolizumab
Ipilimumab
Anti-PD1
Anti-CTLA-4
NSCLC, SqCCa 32
19
95 No None No Extra-serum Negative Cold autoantibody 1+ 1+

*Interval from the first administration of immune checkpoint inhibitors to antibody identification. Red blood cell transfusion history before antibody identification.Hemolysis was determined by integration of laboratory results including reticulocyte, bilirubin, LDH, plasma hemoglobin, and haptoglobin.

Abbreviation: DAT, direct antiglobulin test; PD1, programmed cell death receptor 1; PD-L1, programmed cell death ligand 1; CTLA-4, cytotoxic T-lymphocyte associated protein 4; GB, gall bladder; SqCCa, squamous cell carcinoma; AGC, advanced gastric cancer; ADC, adenocarcinoma; NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma; CCC, cholangiocarcinoma.

Korean J Blood Transfus 2021;32:201-8 https://doi.org/10.17945/kjbt.2021.32.3.201
© 2021 Korean J Blood Transfus